Thiadiazole substituted coumarin derivatives and their use as leukotriene biosynthesis inhibitor

Details for Australian Patent Application No. 2006227524 (hide)

Owner Merck Frosst Canada Ltd

Inventors Laliberte, Sebastien; Grimm, Erich L.; Gareau, Yves; Blouin, Marc; MacKay, Bruce; Juteau, Helene; Gagnon, Marc; Friesen, Richard

Agent Spruson & Ferguson

Pub. Number AU-B-2006227524

PCT Pub. Number WO2006/099735

Priority 60/664,317 23.03.05 US

Filing date 21 March 2006

Wipo publication date 28 September 2006

Acceptance publication date 30 June 2011

International Classifications

C07D 413/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

A61K 31/4245 (2006.01) - Oxadiazoles

A61K 31/433 (2006.01) - Thiadiazoles

A61P 19/02 (2006.01) Drugs for skeletal disorders

C07D 417/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

Event Publications

4 October 2007 PCT application entered the National Phase

  PCT publication WO2006/099735 Priority application(s): WO2006/099735

30 June 2011 Application Accepted

  Published as AU-B-2006227524

27 October 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006227528-Use of ADNF polypeptides for treating peripheral neurotoxicity

2006227522-Anchor assembly with toggle for hollow walls